NOVEL ENTRY INHIBITORS FOR VIRAL HEPATITIS D TREATMENT: BULEVIRTIDE
DOI:
https://doi.org/10.22159/ijcpr.2023v15i1.2065Keywords:
HDV, HBV, Bulevirtide, Entry inhibitor, Compensated cirrhosisAbstract
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Hepatitis delta virus (HDV) is a faulty RNA virus that needs hepatitis B virus surface antigen (HBsAg) for the completion of its life cycle. Hepatitis B virus (HBV) receptor, sodium taurocholate cotransporting polypeptide (NTCP), is used by HDV to infect hepatocytes. The replication of the HDV genome, which is a circular single-stranded RNA and encodes for a single HDAg that occurs in two forms (S-HDAg and L-HDAg), is carried out by the host RNA polymerases. Antiviral therapy is urgently needed to protect patients from hepatocellular carcinoma or end-stage liver disease and poses an important public health issue in many countries. There is still a need for efficient pharmacological therapies for chronic hepatitis D (CHD). A good strategy to stop new infections is to stop virus from entering cells. A new virion entry inhibitor called bulevirtide is now a promising treatment for both infections because it prevents the virion from entering the hepatocyte through the hepatic sodium/taurocholate cotransporting polypeptide Before bulevirtide's conditional approval by the EMA (European Medicines Agency) in July 2020 for the treatment of chronic HDV infection in adult patients with compensated liver disease, therapy options were restricted to the off-label use of pegylated interferon alfa. (NTCP) receptor. We will outline the most recent discoveries about the HDV life cycle that have prompted the development of noveldrug bulevirtide.
Downloads
References
Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf). 2019 Jun 23;7(4):231-45. doi: 10.1093/gastro/goz023, PMID 32477569, PMCID PMC6691517.
Soriano V, de Mendoza C, Trevino A, Ramos Rincon JM, Moreno Torres V, Corral O. Treatment of hepatitis delta and HIV infection. Liver Int. 2022 Jun 24. doi: 10.1111/liv.15345. PMID 35748639.
Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003. doi: 10.1136/gut.18.12.997, PMID 75123.
Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-32. doi: 10.1016/j.jhep.2020.04.008, PMID 32335166.
Koh C, Da BL, Glenn JS. HBV/HDV coinfection: A challenge for therapeutics. Clin Liver Dis. 2019 Aug;23(3):557-72. doi: 10.1016/j.cld.2019.04.005. PMID 31266627, PMCID PMC6659751.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012 Nov 13;1:e00049. doi: 10.7554/eLife.00049. Erratum in: eLife. PMID: 23150796; PMC3485615. 2014;3:e05570.
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85. doi: 10.1016/S0140-6736(10)61931-9, PMID 21511329.
Chang J, Nie X, Chang HE, Han Z, Taylor J. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol. 2008;82(3):1118-27. doi: 10.1128/JVI.01758-07, PMID 18032511.
Lai MM. The molecular biology of hepatitis delta virus. Annu Rev Biochem. 1995;64:259-86. doi: 10.1146/annurev.bi.64.070195.001355, PMID 7574482.
Brillanti S. Management of delta hepatitis 45 Years after the discovery of HDV. J Clin Med. 2022 Mar 13;11(6):1587. doi: 10.3390/jcm11061587, PMID 35329913, PMCID PMC8953848.
Farci P, Anna Niro GG. Current and future management of chronic hepatitis D. Gastroenterol Hepatol (NY). 2018 Jun;14(6):342-51. PMID 30166948, PMCID PMC6111511.
Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Karatayli E. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67(4):1224-36. doi: 10.1002/hep.29658, PMID 29152762.
Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2(12):877-89. doi: 10.1016/S2468-1253(17)30288-1.
Sauter M, Blank A, Stoll F, Lutz N, Haefeli WE, Burhenne J. Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. Anal Bioanal Chem. 2021 Sep;413(22):5645-54. doi: 10.1007/s00216-021-03384-7. PMID 34018034, PMCID PMC8410713.
European Medicines Agency. Hepcludex (bulevirtide) powder for solution for injection: EU summary of product characteristics; 2020.
Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B. J Hepatol. 2016;65(3):483-9. doi: 10.1016/j.jhep.2016.04.013, PMID 27132172.
European medicine agency. Home page in Internet. Committee for Medicinal Products for Human Use (CHMP) Assessment report of bulevirtide. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf.
Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861-7. doi: 10.1016/j.jhep.2012.12.008. PMID 23246506.
Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 2006;43(4):750-60. doi: 10.1002/hep.21112, PMID 16557545.
Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55(3):685-94. doi: 10.1002/hep.24758, PMID 22031488.
Kang C, Syed YY. Bulevirtide: first approval. Drugs. 2020;80(15):1601-5. doi: 10.1007/s40265-020-01400-1, PMID 32926353.
Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490-8. doi: 10.1016/j.jhep.2016.04.016, PMID 27132170.
Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri Petersen M, Bremer B. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68 Suppl 3. doi: 10.1016/S0168-8278(18)30224-1.
Wedemeyer H, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2019;70(1):e81-e132. doi: 10.1016/S0618-8278(19)30141-0.
Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490-8. doi: 10.1016/j.jhep.2016.04.016, PMID 27132170.
Herta T, Hahn M, Maier M, Fischer J, Niemeyer J, Honemann M. Efficacy and safety of bulevirtide plus tenofovir disoproxil fumarate in real-world patients with chronic hepatitis B and D co-infection. Pathogens. 2022 Apr 27;11(5):517. doi: 10.3390/pathogens11050517, PMID 35631038, PMC9143982.
Asselah A, Stefan Arama S, Bogomolov P, Bourliere M, Fontaine H, Gherlanet GS. Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa-2a in patients with chronic hepatitis delta: 24-week interim data of MYR204 Phase 2b study. J Hepatol. 2021;75:S291.
Gilead. Gilead press release Treatment with Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Whttps: 2022. Available from://www.com/news-and-press/press-room/press-releases/2022/6/treatment-with-hepcludex-bulevirtide-meets-primary-endpoint-and-achieves-significant-response-in-chronic-hepatitis-delta-virus-at-48-weeks. [Last accessed on 29 Sep 2022].
Published
How to Cite
Issue
Section
Copyright (c) 2023 SHUKLA A. K., MISRA S.
This work is licensed under a Creative Commons Attribution 4.0 International License.
